StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a report published on Friday morning. The brokerage issued a sell rating on the stock.
Several other equities research analysts have also recently commented on CANF. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, December 31st.
Read Our Latest Stock Report on Can-Fite BioPharma
Can-Fite BioPharma Trading Up 0.6 %
Institutional Investors Weigh In On Can-Fite BioPharma
A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by hedge funds and other institutional investors.
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Stories
- Five stocks we like better than Can-Fite BioPharma
- Following Congress Stock Trades
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What is the FTSE 100 index?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
